• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Infant Bacterial Therapeutics

63.00 SEK

-4.69 %

Less than 1K followers

IBT B

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-4.69 %
+10.53 %
+28.57 %
+24.75 %
+29.10 %
+18.87 %
+38.77 %
-33.05 %
+7.76 %

Infant Bacterial Therapeutics is a biotechnology company focused on developing innovative treatments for inflammatory bowel diseases. The company develops, among other things, medicines to treat and prevent common conditions and diseases in children that occur at early birth. The business is global with a primary presence in Europe and North America. Infant Bacterial Therapeutics was founded in 2011 and is headquartered in Stockholm, Sweden.

Read more
Market cap
848.7M SEK
Turnover
585.14K SEK
Revenue
EBIT %
P/E
Dividend yield-%
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
26.8.
2026

Interim report Q2'26

13.11.
2026

Interim report Q3'26

11.2.
2027

Annual report '26

Regulatory press release5/7/2026, 3:15 PM

Annual General Meeting of Infant Bacterial Therapeutics

Infant Bacterial Therapeutics
Regulatory press release5/6/2026, 12:00 PM

Infant Bacterial Therapeutics AB (publ) Interim report January 1 – March 31, 2026

Infant Bacterial Therapeutics
Regulatory press release4/2/2026, 7:15 AM

Correction: Notice of Annual General Meeting of Infant Bacterial Therapeutics

Infant Bacterial Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release3/30/2026, 12:30 PM

Notice of Annual General Meeting of Infant Bacterial Therapeutics

Infant Bacterial Therapeutics
Regulatory press release3/27/2026, 6:30 AM

Infant Bacterial Therapeutics AB publishes the Annual Report for 2025

Infant Bacterial Therapeutics
Press release3/3/2026, 6:00 AM

Infant Bacterial Therapeutics (IBT) publishes results from ”The Connection Study” in Pediatric Research

Infant Bacterial Therapeutics
Regulatory press release2/6/2026, 6:30 AM

Infant Bacterial Therapeutics AB (publ) Year-end-report January 1 – December 31, 2025

Infant Bacterial Therapeutics
Press release12/11/2025, 5:05 PM

Infant Bacterial Therapeutics secures partnership with BioConnection for production of Drug Product

Infant Bacterial Therapeutics
Regulatory press release11/25/2025, 5:41 PM

IBT changes the IBP-9414 pathway for approval following discussions with the FDA

Infant Bacterial Therapeutics
Press release11/20/2025, 3:42 PM

Infant Bacterial Therapeutics AB secures partnership with Recipharm Advanced Bio for production of drug substance

Infant Bacterial Therapeutics
Regulatory press release11/13/2025, 6:30 AM

Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2025

Infant Bacterial Therapeutics
Regulatory press release10/20/2025, 8:35 AM

Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2026

Infant Bacterial Therapeutics
Press release10/13/2025, 12:35 PM

Registration work for IBT's drug candidate IBP-9414 continues in the US and Europe

Infant Bacterial Therapeutics
Press release9/10/2025, 7:38 AM

IBT presented “Avoiding the severe consequences of NEC” at the NEC Society Symposium in Chicago

Infant Bacterial Therapeutics
Regulatory press release8/20/2025, 6:00 AM

Infant Bacterial Therapeutics AB (publ) Interim report January 1 – June 30, 2025

Infant Bacterial Therapeutics
Press release5/14/2025, 5:30 AM

Infant Bacterial Therapeutics (IBT) to present results of “The Connection Study” at ESPGHAN 2025 in Helsinki

Infant Bacterial Therapeutics
Regulatory press release5/8/2025, 3:45 PM

Annual General Meeting of Infant Bacterial Therapeutics

Infant Bacterial Therapeutics
Press release5/8/2025, 5:00 AM

IBT Submits Clinical Study Report for ‘The Connection Study’ to the FDA

Infant Bacterial Therapeutics
Regulatory press release5/7/2025, 12:30 PM

Infant Bacterial Therapeutics AB (publ) Interim report January 1 – March 31, 2025

Infant Bacterial Therapeutics
Press release4/24/2025, 5:20 AM

Infant Bacterial Therapeutics (IBT) to Present Results of “The Connection Study” at PAS 2025 in Honolulu

Infant Bacterial Therapeutics